No Data
No Data
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
Fort Lee, NJ, May 16, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative
Nuvectis Pharma(NVCT.US) 10% Shareholder Buys US$13,075.6 in Common Stock
$Nuvectis Pharma(NVCT.US)$ 10% Shareholder BENTSUR RON purchased 1,940 shares of common stock on May 14, 2024 at an average price of $6.74 for a total value of $13,075.6.Source: Announcement What is s
Nuvectis Pharma(NVCT.US) Officer Buys US$3,145 in Common Stock
$Nuvectis Pharma(NVCT.US)$ Officer Poradosu Enrique purchased 500 shares of common stock on May 10, 2024 at an average price of $6.29 for a total value of $3,145.Source: Announcement What is statement
Nuvectis Pharma(NVCT.US) 10% Shareholder Buys US$12,800 in Common Stock
$Nuvectis Pharma(NVCT.US)$ 10% Shareholder BENTSUR RON purchased 2,000 shares of common stock on May 10, 2024 at an average price of $6.4 for a total value of $12,800.Source: Announcement What is stat
Nuvectis Pharma(NVCT.US) Officer Buys US$7,034.16 in Common Stock
$Nuvectis Pharma(NVCT.US)$ Officer Shemesh Shay purchased 1,113 shares of common stock on May 10, 2024 at an average price of $6.32 for a total value of $7,034.16.Source: Announcement What is statemen
Nuvectis Pharma Price Target Maintained With a $21.00/Share by HC Wainwright & Co.
Nuvectis Pharma Price Target Maintained With a $21.00/Share by HC Wainwright & Co.
No Data